Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Non-Current Liabilities: 2020-2023

Historic Total Non-Current Liabilities for Kymera Therapeutics (KYMR) over the last 3 years, with Sep 2023 value amounting to $156.8 million.

  • Kymera Therapeutics' Total Non-Current Liabilities rose 25.14% to $156.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $156.8 million, marking a year-over-year increase of 25.14%. This contributed to the annual value of $112.7 million for FY2022, which is 22.89% down from last year.
  • Latest data reveals that Kymera Therapeutics reported Total Non-Current Liabilities of $156.8 million as of Q3 2023, which was up 7.21% from $146.3 million recorded in Q2 2023.
  • Over the past 5 years, Kymera Therapeutics' Total Non-Current Liabilities peaked at $203.2 million during Q4 2020, and registered a low of $112.7 million during Q4 2022.
  • Over the past 3 years, Kymera Therapeutics' median Total Non-Current Liabilities value was $146.3 million (recorded in 2023), while the average stood at $147.5 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first decreased by 29.14% in 2022, then grew by 25.14% in 2023.
  • Over the past 4 years, Kymera Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $203.2 million in 2020, then dropped by 28.05% to $146.2 million in 2021, then fell by 22.89% to $112.7 million in 2022, then increased by 25.14% to $156.8 million in 2023.
  • Its Total Non-Current Liabilities stands at $156.8 million for Q3 2023, versus $146.3 million for Q2 2023 and $151.7 million for Q1 2023.